(Total Views: 570)
Posted On: 05/18/2024 6:21:07 PM
Post# of 148878
Thanks Jake,
yes, it does take some time to assemble these posts, especially when I need to research it out from previous posts or from elsewhere.
they take less time when just writing off the cuff.
regardless of that, I appreciate you telling me that you appreciate what it took to assemble it.
and by the way, your posts are top notch.
Like you and ohm, I find myself on your side of the fence. But if that's true, then why would there have been a fully funded MD Anderson CRC combination Keytruda trial? And I think the reason for that is because, possibly the murine studies were equivocal. Or they could have gone either way. So, Merck would have benefitted with a much more robust combination clinical trial where the true results would be permitted to fully declare themselves.
Merck would have had nothing to lose except more Keytruda in participating in such a trial. Even if the murine study showed very little benefit in the undertaking of a larger trial. Possibly, it might have panned out for Keytruda in a human host and with higher patient participation.
yes, it does take some time to assemble these posts, especially when I need to research it out from previous posts or from elsewhere.
they take less time when just writing off the cuff.
regardless of that, I appreciate you telling me that you appreciate what it took to assemble it.
and by the way, your posts are top notch.
Like you and ohm, I find myself on your side of the fence. But if that's true, then why would there have been a fully funded MD Anderson CRC combination Keytruda trial? And I think the reason for that is because, possibly the murine studies were equivocal. Or they could have gone either way. So, Merck would have benefitted with a much more robust combination clinical trial where the true results would be permitted to fully declare themselves.
Merck would have had nothing to lose except more Keytruda in participating in such a trial. Even if the murine study showed very little benefit in the undertaking of a larger trial. Possibly, it might have panned out for Keytruda in a human host and with higher patient participation.
(6)
(0)Scroll down for more posts ▼
